Proxima B: (GX29639) 31/03/2016
Prospective, multicentre epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration.
This is an observational study which aims to recruit 200 patients with GA secondary to AMD. The expected maximum duration of patient follow-up in this study is 60 months. Visual function and anatomical measurements will be taken on selection, at the basal moment (day 1) and then every 6 months.
The principal aims of this epidemiological study are to assess the progression of geographic atrophy (GA) through eye fundus autofluorescence (FAF) and to determine the prognostic value of the Complement Factor I (CFI) biomarker profile in the average variation of the GA area with regard to the basal moment.
This study’s secondary aims are to carry out assessments of the visual function and to assess variations over time in a series of results reported by the patients.
Principal inclusion criteria
Patients older than 50 with:
- Unilateral GA secondary to age-related macular degeneration (AMD).
- GA secondary to AMD in one eye and choroidal neovascularisation (NVC; active or treated) secondary to AMD in the contralateral eye.
If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155.
Our team of professionals will answer you as soon as possible and we will assess whether you are eligible.